
- /
- Supported exchanges
- / US
- / ENGN.NASDAQ
enGene Holdings Inc. Common Stock (ENGN NASDAQ) stock market data APIs
enGene Holdings Inc. Common Stock Financial Data Overview
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). enGene Holdings Inc. is based in Montreal, Canada.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get enGene Holdings Inc. Common Stock data using free add-ons & libraries
Get enGene Holdings Inc. Common Stock Fundamental Data
enGene Holdings Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -62 206 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-01-31
- EPS/Forecast: -0.3783
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
enGene Holdings Inc. Common Stock News

NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
NewAmsterdam Pharma N.V. NAARDEN, The Netherlands and MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage...


Forbion co-leads €129 million Series A financing of VectorY, one of the largest private biotech financings in Europe in 2023
Round co-led by Forbion and EQT Life Sciences Financing will support clinical development of VTx-002, a potentially disease-modifying therapy for Amyotrophic Lateral Sclerosis (ALS) and additional pip...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.